Sleep disorders in women

Antonio Culebras MD FAAN FAHA FAASM

Sleep Disorders

Updated 10.27.2024
Released 04.05.2010
Expires For CME 10.27.2027

Sleep disorders in women

Author: Antonio Culebras MD FAAN FAHA FAASM

See Contributor Disclosures

Sleep disorders in women

In This Article

Quick Link

Introduction

Overview

The author describes the idiosyncrasies of sleep in women, including changes that occur with the biological life cycles of menstruation, pregnancy, and menopause. Each phase increases the risk of sleep disturbance in unique ways that require distinct management. Research has revealed novel aspects of sleep pathology and management in women.

Key points

	• Although women sleep better than men, 46% complain of trouble sleeping almost every night.
	• Several sleep-related disorders, including restless legs syndrome, insomnia, and sleep-related eating disorder, are more prevalent and severe in women.

Historical note and terminology

Research has revealed novel aspects of sleep pathology and management in women (22). A study by Hu and colleagues showed that snoring women had more strokes (41). In a study of 71,779 female nurses 40 through 65 years of age without previously diagnosed vascular disease followed for 8 years, the authors found that the age-adjusted relative risk of stroke was 1.60 (95% CI, 1.21 to 2.12) for occasional snorers and 1.88 (95% CI, 1.29 to 2.74) for habitual snorers. The study did not identify patients with sleep apnea, but as habitual snoring is a common marker of obstructive sleep apnea, it remains inescapable to assume that obstructive sleep apnea was the background risk factor for vascular disease. Research results show that women with sleep apnea are indeed at higher risk of stroke than men, but the mechanisms of this phenomenon remain elusive (18).

Clinical manifestations

Presentation and course

	• The menstrual cycle, pregnancy, and menopause are the principal modifying factors that increase the risk of sleep disturbance.
	• The cause of poor sleep quality in menopause is likely multifactorial.

Women generally sleep better than men (10). They have more deep sleep, a slower age-related decline in delta activity (the marker of deep sleep), and twice as many sleep spindles (31; 28). And yet, only 40% of women sleep well almost every night, and 46% of women complain of trouble sleeping almost every night (66). Women go through phases in their life cycle that increase the risk of sleep disturbance. The menstrual cycle, pregnancy, and menopause are the principal modifying factors.

Epochs

Menstrual cycle. Menstrual-related hypersomnia is characterized by recurrent episodes of sleepiness in association with the menstrual cycle (04). The condition generally occurs within the first months following menarche. Episodes of hypersomnia last one week and resolve with the occurrence of menses. Oral contraceptives eliminate sleepiness, suggesting a hormonal imbalance underlying this form of hypersomnia.

Both subjective and objective sleep changes occur during the menstrual cycle. In women with premenstrual symptoms or painful menstrual cramps, decreased sleep quality in the premenstrual phase and menstruation are common. Increased sleep spindle activity has been noted from the follicular to luteal phase, suggesting progesterone effect. Luteal phase changes include reduced rapid eye movement sleep. Short sleep duration is associated with irregular menstrual cycles, and menstrual-related disorders should be considered when assessing women's sleep complaints (07).

Pregnancy. Thirty percent of pregnant women rarely or never get a good night’s sleep whereas 84% experience a sleep problem a few nights per week compared to 67% of women overall. Forty percent report symptoms of sleep disorders, including snoring, sleep apnea, or restless legs syndrome (66). More information about sleep disorders during pregnancy is covered in the “Pregnancy” section below.

There is an increased association between women with higher Epworth Sleepiness Scale (EDS) scores and planned cesarean delivery. Severe EDS (> 16) was associated with gestational diabetes in pregnant women in a small sample size (13). Future studies in larger samples need to confirm the association of severe EDS and gestational diabetes.

Postpartum. Eighty-four percent of women experience insomnia a few nights per week following delivery. Forty-two percent rarely or never get a good night’s sleep, whereas 19% experience postpartum blues or depression (33). After parturition, sleep apnea improves significantly, both in REM (64 ± 11 to 22 ± 4 events per hour) and nonREM sleep (65 ± 18 to 18 ± 4 events per hour) (27).

Menopause. Postmenopausal sleep complaints increase to reach 35% to 60% of all women. In the absence of hormone replacement therapy, the risk of developing sleep apnea increases (11); in fact, in postmenopausal women, sleep apnea severity tends to equal that in men. Menopausal hot flashes display a circadian variation, with peak frequency in late evening, and are related to a change of unknown etiology in the central thermoregulatory response. Eighty percent of peri- and postmenopausal women with severe hot flashes have chronic insomnia (72). In another study of 206 menopausal women, the overall prevalence of insomnia was four to five times a week in 62% of the women, with 68.9% complaining of hot flashes (39). In a later study, the same authors found that hot flashes were associated with insomnia and polysomnographic alterations suggestive of insomnia. Hot flashes were more frequent among women with insomnia disorders (25.5%) and isolated insomnia symptoms (23.0%) when compared with good sleepers (12.6%) (p=0.01) (40).

In a meta-analysis aimed to determine the global prevalence of sleep disorders during menopause, the authors found that the overall prevalence of sleep disorders among postmenopausal women was 51.6% (95% CI: 44.6% to 58.5%) (82). Restless legs syndrome had a prevalence of 63.8% (95% CI: 10.6% to 96.3%). The authors concluded that sleep disorders during menopause are common and significant, recommending pertinent interventions related to the health and hygiene of sleep for women in menopause.

Old age. In an actigraphic study of community-dwelling older women, longer sleep duration and greater sleep fragmentation were associated with poorer performance and impairment in some cognitive domains. Women with dementia may have driven the results of the study because disturbed sleep and cognitive performance are intrinsic to dementia (87).

Sleep disorders are common among women veterans with insomnia, sleep-disordered breathing, and insufficient sleep prevailing (60). Women veterans should be screened and treated for sleep-disordered breathing, and behavioral and lifestyle factors contributing to insufficient sleep should be addressed. High rates of psychiatric comorbidities, such as posttraumatic stress disorder and depression are contributing factors that complicate management.

Sleep disorders

Sleep apnea. Outside pregnancy, sleep apnea syndrome of moderate to severe intensity (Apnea Hypopnea Index [AHI], more than 15 respiratory events/hour of sleep) is found in 9% of 50- to 70-year-old women (76). For mild cases (AHI, more than five events per hour), the ratio changes to 15% of men and 10% of women. Gender differences in sleep apnea are related to anatomical differences, with more upper body fat distribution in men and increased ventilation and upper airway muscle activity caused by the hormonal action of progesterone in women (46). In general, the risk of sleep apnea increases after menopause, presumably when the influence of progesterone declines and the anatomical differences with men become less marked; the risk in women tends to approach that in men until the age of 65 years, which is the age when the prevalence of sleep apnea peaks in women. A prospective study evaluated differences in the clinical characteristics of women and men with obesity hypoventilation syndrome in a large cohort of patients with obstructive sleep apnea (06). Among 1973 consecutive patients, 617 women were diagnosed with obstructive sleep apnea, and 144 patients (96 women) suffered from obesity hypoventilation syndrome. The prevalence of obesity hypoventilation syndrome among women and men was 15.6% and 4.5%, respectively (P < 0.001), indicating that post-menopausal women with obstructive sleep apnea have the highest prevalence of obesity hypoventilation syndrome.

Central sleep apnea occurs in women with congestive heart failure (odds ratio 3.5 for women) but with much lower frequency than in men (43). Women with sleep apnea complain of headaches in the morning more frequently than men, perhaps related to allodynia (lowering of pain threshold) in women with migraines (103), a condition that is well known to affect women more often than men at all ages. On the other hand, men with sleep apnea have a higher risk of suffering motor vehicle accidents, a feared complication of sleep apnea syndrome.

In China, Chang and colleagues found that young women (35 years old and younger) with sleep apnea are at higher risk of stroke (18). Using a universal insurance claims database, Chang and colleagues identified a large cohort of patients with sleep apnea (AHI > 5/hr) using polysomnography. The authors compared the sex- and age-specific stroke risk with a control group. Stratified by age, the effects of sleep apnea on stroke risk in women decreased with age (adjusted HR 4.90, 95% CI 1.93 to 12.4 for subgroup aged 20 to 35 years; adjusted HR 1.64, 95% CI 1.01 to 2.65 for subgroup aged 36 to 50 years; adjusted HR 1.38, 95% CI 1.01 to 1.89 for subgroup aged 51 to 65 years).

Severe obstructive sleep apnea during REM sleep (REM AHI > 30) was associated with a thicker carotid intima (52). This was noted in the community-based "Sleep and Health in Women" (SHE) cohort study of 400 women. Study subjects underwent polysomnography and a high-frequency ultrasound of the common carotid artery to assess the individual thickness of the layers of the artery wall. After 10 years, the study of 201 of the original participants free of known atherosclerotic disease at baseline and without CPAP treatment for obstructive sleep apnea and diabetes showed that severe obstructive sleep apnea during REM sleep (REM AHI > 30) was associated with a thicker intima.

In a study of 53 placentas, 10 women (19%) had obstructive sleep apnea, and the weight of their placentas was significantly higher compared with the placentas of the controls (526.1 ± 83.9 vs. 425.7 ± 95.5 g, p = 0.00) (48). The authors concluded that maternal obstructive sleep apnea is associated with increased placental weight correlating with obstructive sleep apnea severity and neonatal adiposity independently of maternal BMI. Placental leptin overexpression may mediate these findings.

Women with polycystic ovary syndrome have an increased risk for sleep-disordered breathing, which should be treated to mitigate health impacts (08). Women with polycystic ovary syndrome should be screened for sleep-disordered breathing.

In a study of 774 women (40 to 67 years old) from 15 centers in seven countries (European Community Respiratory Health Survey, 2010-2012), middle-aged women with low serum estrogen and progesterone levels were more likely to snore and report symptoms of obstructive sleep apnea (86).

High-altitude periodic breathing. Women are more resistant to high-altitude periodic breathing than men. Males tend to have higher central apnea indices and start developing sleep-related periodic breathing at lower altitudes than women. Gender differences are maintained even after 10 days of acclimatization (53).

Restless legs syndrome. Restless legs syndrome is a frequently undiagnosed sensorimotor disorder that impairs sleep and reduces the quality of life. It is characterized by an urge to move the legs, usually with uncomfortable leg sensations, a worsening of symptoms at rest or inactivity, an aggravation of symptoms in the evening and at night, and relief with movement, walking, or stretching. Restless legs syndrome affects 5% to 10% of the general population, increases with age, and is more prevalent in women (09; 01). Blood pressure and heart rate rise with periodic limb movements, increasing the risk of hypertension and cardiovascular disease (75). Restless legs syndrome is more common in older women than in older men and appears with relative frequency during pregnancy. Restless legs syndrome affects one third of pregnant women during their third trimester and usually improves after delivery (67). The transient pregnancy restless legs syndrome form is a significant risk factor for the development of a future chronic idiopathic restless legs syndrome form, and for a new transient symptomatology in a future pregnancy. In a study, the authors found that mothers of children with ADHD had an increased risk of having restless legs syndrome (32). Another study found a possible association with serum iron level disturbances in pregnancy (63).

In a prospective study of 57,417 women (mean age 67 years) with physician-diagnosed restless legs syndrome from the Nurses' Health Study, researchers investigated total and cardiovascular disease mortality relative to those without restless legs syndrome (50). The authors found that participants with restless legs syndrome had a significantly higher risk of cardiovascular disease mortality (adjusted HR 1.43, 95% CI 1.02-2.00) relative to those without restless legs syndrome after adjustment for potential confounders. The authors concluded that women with restless legs syndrome had a higher cardiovascular disease mortality rate, which may not be fully explained by common co-occurring disorders of restless legs syndrome.

In a study of 136 participants with long-haul COVID-19 (89.7% females, age 46.9 ± 12.9 years) and 136 controls (65.4% females, age 49.2 ± 15.5), the prevalence of restless legs syndrome in females with long-haul COVID-19 was 5.7% pre-COVID-19 and 14.8% post-COVID-19 (P < .01) versus 6.7% in control females (98). The severity of restless legs syndrome was moderate in both groups. The authors concluded that the prevalence of restless legs syndrome significantly increased in the long-haul COVID-19 state, suggesting that immunological mechanisms may be at play in the production of restless legs syndrome symptoms.

Insomnia. Insomnia is defined as the repeated difficulty initiating and maintaining sleep. The difficulty sets in despite adequate opportunity to sleep and results in daytime impairment (04). Insomnia in women shows some variations, mostly related to biological life cycles. The menstrual phase worsens sleep quality in 31% of menstruating women (58). Pregnant women frequently describe difficulty sleeping.

Insomnia complaints increase in menopause, an epoch in the life cycle that is associated with sleep complaints in 35% to 60% of women (105). Commonly associated disorders are pain syndromes, fibromyalgia, depression, restless legs syndrome, and nocturnal sleep-related eating disorder. Insomnia in menopause should be considered a multifactorial alteration in which aging plays an important role.

Lower sleep efficiency and more minutes awake after sleep onset were independently associated with higher circulating levels of proinflammatory factors in midlife women (69). Factors studied were interleukin-6 and von Willebrand factor antigen. The study comprised 295 peri- and postmenopausal women aged 40 to 60 years who completed 3 days of wrist actigraphy. The findings suggest that sleep disturbances are associated with greater circulating inflammation in midlife women.

Hypersomnia and excessive daytime sleepiness. In a study of sleep duration and obesity among 7094 community-dwelling Chinese adults the authors found that long sleep duration is associated with general obesity in Chinese women (101). On the contrary, among men long sleepers (≥ 9 h/d) presented lower risks of developing abdominal obesity compared with individuals who slept 7 to 8 hours/day. Menstruation-related hypersomnia may be an underrecognized disorder (95).

Sleep-related eating disorder. Sleep-related eating disorder refers to recurrent episodes of involuntary eating and drinking during partial arousals from sleep with adverse consequences. Episodes occur without control by the individual. The episodes are generally not recalled, but a small number of patients have some awareness and retain fragmented memory of the episodes. The diagnostic criteria set forth by the International Classification of Sleep Disorders (ICSD-2) include consumption of peculiar foods in bizarre combinations and, at times, with inedible substances, like frozen pizza, buttered cigarettes, raw bacon, cat food, coffee grounds, and cleaning solutions (04). In addition, there is sleep disruption with complaints of nonrestorative sleep, daytime fatigue, and somnolence. Sleep-related injuries may occur, and examples are burns, lacerations, poisoning, and injuries from inappropriate use of kitchen utensils or internal lesions from eating inedible substances. Patients may gain weight (mean weight gain 12.6 kg) (85) and become depressed. Sweets, pasta, peanut butter, milk, and dairy products are preferred items. Depending on the series reported, 60% to 83% of patients with sleep-related eating disorder are women (99). Sleep-related eating disorder is more common between the ages of 22 and 40 years. Episodes may occur nightly, sometimes several times per night.

The impact of nightshift work in women was investigated in a study conducted with face-to-face interviews (97). The study included 712 women diagnosed with incident invasive breast cancer before treatment and 742 age-matched controls. Night-shift work was associated with an increased risk of breast cancer (OR (95% CI): 1.34 (1.05 to 1.72)). Compared to women with a sleep duration of 6.1 to 8.9 hours per day, women who had shorter ((≤6.0 h/day) (OR (95% CI): 1.53 (1.10 to 2.12)) and longer (≥9.0 h/day) sleep duration ((OR (95% CI): 1.59 (1.17 to 2.17)) also had an increased risk of breast cancer. Daytime napping was associated with a reduced risk of breast cancer among night-shift workers (OR (95% CI): 0.57 (0.36 to 0.90)). The authors concluded that nightshift work and shorter and longer sleep duration are associated with an increased breast cancer risk.

Prognosis and complications

In an analysis of sleep duration and risk of selected site-specific and groups of cancer among a large prospective cohort of women in California, the authors studied 101,609 adult females participating in the California Teachers Study (42). All sites of invasive cancer prospectively diagnosed from 1995 through 2011 were identified through linkage to the California Cancer Registry (n = 12,322). Site-specific cancers analyzed were breast (n = 5053), colorectal (n = 983), lung (n = 820), melanoma (n = 749), and endometrial (n = 957). Estrogen-mediated cancers, consisting of breast, endometrial, and ovarian cancer (n = 6458), were independently analyzed. Sleep duration was based on self-report of average time sleeping in the year prior to baseline. The authors found that site-specific cancers were generally near or below 1 for short sleepers (fewer than 6 hours per night) and above 1 for long sleepers (10+ hours per night); confidence intervals, however, were wide. Compared to average sleepers (7 to 9 hours per night), long sleepers had an increased risk of the group of estrogen-mediated cancers (HR 1.22, 95% CI, 0.97 to 1.54, p (trend) = 0.04). The authors concluded that longer sleep may be associated with increased risk of estrogen-mediated cancers, but additional studies are warranted.

In a prospective study, the association between obstructive sleep apnea and incident psoriasis and psoriatic arthritis was investigated in 71,598 women over an 11-year period (1997 to 2008) in the Nurses' Health Study (20). Over the follow-up period, there were 524 cases of psoriasis. The age-adjusted relative risk (RR) of psoriasis among women with obstructive sleep apnea was 2.19 (95% CI, 1.39 to 3.45). Further adjusting for night shift work, hypertension, cardiovascular disease, and type 2 diabetes, the multivariate RR was 1.91(95% CI, 1.20 to 3.05). Obstructive sleep apnea was not associated with an increased risk of psoriatic arthritis; however, the study showed that women with obstructive sleep apnea had a significantly increased risk of psoriasis.

Shorter sleep time assessed with actigraphy and poorer subjective sleep quality were associated with increased carotid atherosclerosis (carotid ultrasound-intima media thickness plaque) among midlife women (91). The associations persisted after adjusting for vascular risk factors.

In a polysomnographic study of 177 consecutive women (89 with gestational diabetes mellitus and 88 controls) in the third trimester of pregnancy, the authors found that obstructive sleep apnea (more than five episodes per hour) prevalence during the third trimester of pregnancy was not significantly different in patients with gestational diabetes mellitus than without gestational diabetes mellitus (02). Total sleep time showed an inverse relationship with insulin resistance in pregnant women. The results are interesting because obstructive sleep apnea increases the risk of type 2 diabetes and hyperinsulinemia whereas pregnancy increases the risk of obstructive sleep apnea.

Biological basis

Menstruation is controlled by hormonal changes, which in turn may affect sleep. Estrogen levels are higher in the follicular phase (between days 6 and 14 of the cycle) when the endometrium grows and thickens. Simultaneously, the ovarian follicles grow in response to the action of the follicle-stimulating hormone, but only one follicle will develop into a mature egg. On day 14, the ovary releases the egg in response to an increase in luteinizing hormone, a process that is known as ovulation. The luteal phase ensues as the egg travels via the fallopian tubes to the uterus, where it finds a receptive lining facilitated by increasing progesterone levels. When pregnancy fails to occur, estrogen and progesterone levels drop, and the lining of the uterus is shed into the vagina during days 1 to 6 of the menstrual cycle, a phenomenon identified as menstruation. On average, the cycle is 28 days long, ranging between 21 and 35 days.

Estrogen decreases REM sleep in rats, but in humans, exogenous exposure to estrogen increases REM sleep (57). Progesterone increases the latency to REM sleep and decreases the proportion of REM sleep. Progesterone is related to decreased upper airway muscle activity (26). In the luteal phase, when the influence of progesterone is maximum, upper airway muscle activity decreases, and the tongue muscle activity increases, improving the opening of the upper airway during that portion of the cycle (80). Measurements of upper airway resistance have shown a lower resistance in the luteal phase.

Menopause officially ensues one year following cessation of menstrual periods, but hormonal changes begin 7 to 10 years before the final menses. Estradiol and progesterone secretion decrease, whereas follicle-stimulating hormone and luteinizing hormone increase. The cause of poor sleep quality in menopause is likely multifactorial. Women have greater susceptibility than men to develop depression. In addition, psychosocial factors such as responsibilities towards home, children, spouse, and jobs, as well as lifestyle changes imposed by retirement coupled with increased life expectancy, contribute to sleeplessness in the postmenopausal years. Loss of estrogen and progesterone leads to difficulty with sleep maintenance, but the main significant finding is nocturnal sleep fragmentation by arousals and awakenings. In one study, sleep duration and wake after sleep onset did not vary by menopause transition (61). Elevated beta EEG power in NREM sleep was apparent among women who transitioned to post-menopause, suggesting that the menopausal transition is associated with physiological hyperarousal during sleep, and this was independent of self-reported hot flashes.

Sleep alterations caused by the aging process interact with sleep disturbances precipitated by menopausal changes. Aging is associated with advanced sleep onset and core temperature phases, at a time when light as a Zeitgeber becomes less influential in maintaining the circadian cycle. Weakening of circadian and homeostatic processes contribute to sleep disturbances. In post-menopause, older women experience a phase advancement of 1.1 hours in melatonin acrophase.

Restless legs syndrome is a dysfunction of the dopamine system. Primary restless legs syndrome is idiopathic and may be familial with a genetic background (78), whereas secondary restless legs syndrome occurs with iron deficiency, renal failure, pregnancy, and advanced peripheral neuropathy of any etiology. Iron is a cofactor necessary for the production of dopamine, and its deficiency is indicated by ferritin levels in blood of less than 50 ng/ml.

Triggering factors of sleep-related eating disorders are hypoglycemic states, Kleine-Levin syndrome, reflux esophagitis, peptic ulcer disease, and zolpidem administration (65). Cessation of smoking or drinking alcohol has also been reported as a triggering event (85). Sleep-related eating disorders should be considered a final common pathway emerging from a broad range of clinical disorders. The episodes appear in all stages of sleep and, therefore, may occur at any time during the night.

In a study of 29,681 women (18 to 69 years old) residing in a subarctic region, the Pittsburgh Sleep Quality Index (PSQI) was used to assess severe sleep problems for one month (94). Overall, 24.2% of women reported severe sleep problems. Women responding in the winter presented with a higher prevalence of severe sleep problems than those responding in the summer (PR 1.21; 95% CI, 1.15 to 1.28). The authors conclude that the findings should stimulate the development of preventive strategies and interventions for women in the subarctic who suffer from sleep problems.

Diagnostic workup

Overnight ambulatory unassisted polysomnography is a reasonable test to use in the third trimester of pregnancy at home in women who snore, report sleepiness, and show hypertension. The aim would be to objectively demonstrate and measure clinically significant sleep apnea. A sleep Apnea Hypopnea Index (AHI) of five events per hour of sleep or more might indicate continuous positive airway pressure (CPAP) treatment.

The presenting complaint of restless legs syndrome and sleep-related eating disorder may be fatigue, nonrestorative sleep, or insomnia. It is important to reach a correct diagnosis because there is specific treatment in most cases. Referral to a sleep disorders center and, in many instances, overnight polysomnography are recommended to reach a correct diagnosis and identify comorbid sleep-related conditions that may act as precipitating factors.

Periodic limb movements are repetitive movements of the legs, sometimes of the arms, occurring at 5- to 90-second intervals, often associated with arousals that reduce the quality of nocturnal sleep. The presence of periodic limb movements on the polysomnogram supports the restless legs syndrome diagnosis.

Periodic limb movements in sleep (polysomnogram)

Periodic limb movements can be used as an accessory diagnostic criterion in difficult-to-diagnose patients with restless legs syndrome (25). They may give information on restless legs syndrome severity and on the amount of sleep instability and fragmentation.

The Insomnia Symptoms Questionnaire (ISQ) is a short and cost-effective tool that can be quickly employed in large observational studies or in clinical practice where perinatal women are seen. It was evaluated in 143 pregnant women at 12 weeks gestation (70), and it was compared to traditional measures of sleep from sleep diaries, actigraphy, and the Pittsburgh Sleep Quality Index. The results showed that ISQ identified 12.6% of the sample as meeting a case definition of insomnia, consistent with established diagnostic criteria. The ISQ had high specificity (most greater than 85%), but sensitivity varied according to which sleep measure was used as the validating criterion. The authors concluded that insomnia is a health problem for many pregnant women at all stages in pregnancy and that the data support the validity and reliability of the ISQ to identify insomnia in pregnant women.

Management

Recommendations to improve hot flashes include regulating the core body temperature, cooling ambient temperature, dressing in layers, drinking cold liquids, avoiding caffeine and nicotine, and losing weight. Estrogen replacement and administration of gabapentin or clonidine, along with relaxation techniques, have been recognized as effective remedies. Hormone replacement therapy users report better quality of sleep than nonusers, even three years after hormone replacement therapy, perhaps through modulation of the reticular activating system. Women should be aware that significant risks are associated with hormone replacement therapy, including increased risk of breast cancer, stroke, heart disease, and vascular dementia (34; 68; 84).

Nonpharmacologic therapy of restless legs syndrome and periodic limb movements rests on abstention from nicotine, caffeine, and alcohol as well as discontinuation of medications that exacerbate restless legs syndrome (sedating antihistamines, dopamine-receptor antagonists, and antidepressants except bupropion). Leg massages, hot baths, stretching, and walking alleviate the symptoms. Iron replacement should be added when appropriate. The goal of therapy is to maintain ferritin levels above 50 ng/ml. Treatment consists of ferrous sulfate 325 mg plus 100 mg of vitamin C, 1 hour before or up to 2 hours after a meal, three times daily. In severe iron deficiency expressed by a ferritin level in blood under 10 ng/ml, consideration should be given to administration of iron via intravenous infusions of 100 to 125 mg at least 2 days apart (74). Pharmacologic options are dopamine agonists such as pramipexole (100) and ropinirole, as drugs of choice, followed by gabapentin and low-potency opioids (93). Levodopa preparations are also effective, but with continued use, they may cause augmentation, a peculiar worsening of symptoms earlier in the day. In consequence, levodopa preparations should be limited to transient situations such as long flights, car drives, and shows with forced confinement to a seat. Dopamine agonists are safe, but some individuals develop excessive somnolence and compulsive behaviors, including hypersexuality and pathologic gambling (92).

For nonpregnant women, the general approach to treatment of insomnia starts with the investigation of possible physical factors affecting the quality of sleep, including sleep apnea, restless legs syndrome, and periodic limb movements. When these conditions are suspected, referral to a sleep specialist and performance of polysomnography are indicated. Cognitive behavioral therapy alone or in combination with pharmacologic treatment with antidepressants, anxiolytics, or hypnotics is effective and most often should be preceded by a consultation with a sleep specialist. Preliminary findings support the notion that telephone-delivered cognitive behavioral therapy for treatment of chronic insomnia may be useful (05). Some individuals with insomnia may also benefit from pamphlet-delivered cognitive behavioral therapy with brief telephone support.

CBT-Meno (cognitive behavior therapy for menopausal symptoms) sessions (including psychoeducation and cognitive and behavioral strategies for vasomotor and depressive symptoms, anxiety, sleep difficulties, and sexual concerns) were particularly effective in improving self-reported vasomotor symptoms, depressive symptoms, sleep difficulties, and sexual concerns (36). The results suggest that this protocol effectively targets commonly reported menopausal symptoms.

In another study, 117 postmenopausal women (56.34 ± 5.41 years) with peri- or postmenopausal onset of chronic insomnia were randomized to three treatment conditions: sleep hygiene education control, sleep restriction therapy, and cognitive-behavioral therapy for insomnia (45). Cognitive-behavioral therapy for insomnia and sleep restriction therapy reduced depressive symptoms, dysfunctional beliefs about sleep, and pre-sleep somatic hyperarousal in postmenopausal women, with cognitive-behavioral therapy for insomnia producing superior results.

In a randomized, double-blind, placebo-controlled clinical trial, three groups of 20 postmenopausal women were studied with the objective of evaluating the efficacy of venlafaxine and citalopram compared to placebo in the treatment of sleep disturbances in healthy postmenopausal women (24). The patients took venlafaxine 75 mg/daily (group I) or citalopram 20 mg/d (group II) or placebo (group III). Each patient filled out Pittsburgh sleep quality index (PSQI) and Pittsburgh and Beck depression questionnaires. The frequency and severity of daily hot flashes were measured through diaries. Citalopram and venlafaxine were equally more effective than placebo in reducing sleep disturbance and severity of hot flashes, whereas citalopram was more effective in reducing the frequency of hot flashes than venlafaxine. Venlafaxine was more effective than citalopram in the treatment of depression in postmenopausal women. In another study of 546 peri- and postmenopausal women with insomnia and bothersome hot flashes, the authors concluded that cognitive behavioral therapy is a first-line treatment in healthy midlife women with insomnia symptoms and moderately bothersome hot flashes (38).

The treatment of sleep-related eating disorders includes the elimination of triggering factors and treatment of underlying disorders such as sleep apnea. Topiramate is effective in doses of 100 to 200 mg at bedtime. Alternative therapies are dopamine agonists, opiates, clonazepam, bupropion, trazodone, and levodopa.

In a study of 55 early postpartum women, Zaremba and colleagues found that 45 degrees upper body elevation increased upper airway cross-sectional area and mitigated sleep apnea (104). They concluded that elevated body position might improve respiratory safety in women early after delivery.

Using data from 25,389 patients with a diagnosis of obstructive sleep apnea selected from the Danish National Patient Registry for the period 1999 to 2009, the authors studied all-cause mortality from obstructive sleep apnea in middle-aged and elderly males and females who were treated, or not, with CPAP (44). They found that female patients with obstructive sleep apnea had a lower mortality than males, irrespective of whether they received CPAP treatment. CPAP treatment improved survival (HR= 0.62 [P< 0.001]), and this effect was dependent on gender. Survival was increased by CPAP in males 40 to 59 years of age and males greater than 60 years of age, but no such effect was observed in females. The authors concluded that CPAP therapy is associated with reduced all-cause mortality in middle-aged and elderly males, but no significant effect was found in females.

Tirzepatide is a weight-reduction medication. In the SURMOUNT-OSA randomized, double-blind, controlled study, the efficacy and safety of tirzepatide for treating moderate to severe obstructive sleep apnea in people with obesity were evaluated; 32.9% of the subjects were women (56). The authors found that tirzepatide reduced the apnea-hypopnea index (AHI), body weight, hypoxic burden, C-reactive protein concentration, and systolic blood pressure, and patients reported improved sleep-related outcomes. After 52 weeks of treatment, approximately one half of patients taking tirzepatide met the end-point criteria of fewer than 5 to 14 AHI events per hour of sleep and an Epworth Sleepiness Score of less than 10 points, making them eligible for positive airway pressure discontinuation. The authors concluded that tirzepatide provides clinically meaningful improvement in obesity-related obstructive sleep apnea.

The findings of a meta-analysis of 15 studies compared with placebo revealed that hormone therapy improved self-reported sleep outcomes but not sleep parameters measured by polysomnography (73). Subgroup analyses showed that 17β-estradiol and conjugated equine estrogens improved sleep quality, whereas transdermal administration was more beneficial than oral administration (P < 0.00001). The combination of estrogen and progesterone had a beneficial effect on sleep disturbance (P < 0.00001), whereas estrogen monotherapy did not. The results also showed that estrogen/micronized progesterone and estrogen/medroxyprogesterone acetate could alleviate sleep disturbance. The authors concluded that hormone therapy has some beneficial effect on sleep disturbance, whereas the formulations and routes of administration influence the effect size.

The efficacy and safety of lemborexant (LEM), a competitive dual orexin receptor antagonist, was assessed for 12 months in a subgroup of women aged 40 to 58 years (90). This was a randomized, double-blind, placebo-controlled study of adults with insomnia disorder (N = 949). Assessments included patient-reported sleep- and fatigue-related measures and adverse events. Greater improvement from baseline in Insomnia Severity Index total score and Fatigue Severity Scale total score were seen at six months. Benefits continued through 12 months, and adverse events were mild to moderate in severity. The authors concluded that subjective sleep parameters improved over time in midlife women. In the authors’ opinion, lemborexant may be a potential treatment option for midlife women with insomnia.

Special considerations

Pregnancy

	• Sleep apnea affects 10% of pregnant women, particularly those who are obese, with the incidence reaching a peak in the third trimester of pregnancy.
	• The notion of a pathogenic link between sleep apnea and preeclampsia opens opportunities for prevention and treatment.

Thirty percent of pregnant women rarely or never get a good night’s sleep, whereas 84% experience a sleep problem a few nights per week compared to 67% of women overall. Forty percent report symptoms of sleep disorders, including snoring, sleep apnea, or restless legs syndrome (66). The diagnosis of insomnia during pregnancy has increased over time, disparately affecting women of low socioeconomic status. A diagnosis of insomnia is an independent predictor of severe maternal morbidity (47). Growing evidence links sleep disturbances with adverse maternal and fetal outcomes (51).

Women experience significant sleep disruption, inadequate sleep, and high rates of symptoms of sleep disorder throughout pregnancy. In a study of 2427 women, subjects completed an internet-based survey that included the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, vitality scale of the Short Form 36 Health Survey (SF-36) along with the Insomnia Severity Index (ISI), Berlin questionnaire, International Restless Legs Syndrome (IRLS) question set, and a short version of the Pregnancy Symptoms Inventory (PSI) (64). Across all months of pregnancy, women experienced poor sleep quality (76%), insufficient nighttime sleep (38%), and significant daytime sleepiness (49%). All women reported frequent nighttime awakenings (100%), and most women took daytime naps (78%). Symptoms of insomnia (57%), sleep-disordered breathing (19%), and restless legs syndrome (24%) were commonly observed. There was no difference across the month of pregnancy for insomnia, sleep-disordered breathing, daytime sleepiness, or fatigue. Frequent urination (83%) and difficulty finding a comfortable sleep position (79%) contributed to disturbed sleep. The authors of the study suggest that all women should be screened and treated for sleep disturbances throughout pregnancy, especially given the risks of inadequate sleep and sleep disorders on fetal, pregnancy, and postpartum negative outcomes.

In the multicenter prospective Life-ON study, 439 pregnant women at a gestational age between 10 and 15 weeks were recruited for home polysomnography performed between the 23rd and 25th week of pregnancy (59). Sleep-related questionnaires were conducted nine times during pregnancy and 6 months postpartum. The study found poor quality sleep and insomnia in 34% of women in the first trimester of pregnancy, 46% of women in the third trimester, and 71% of women in the first month after delivery. Excessive daytime sleepiness peaked in the first trimester and decreased in the third trimester. Restless legs syndrome was observed in 25%, with a peak in the third trimester of pregnancy. The prevalence of sleep-disordered breathing (RDI≥5) was 4.2% and correlated positively with BMI. The authors concluded that sleep disorders are highly frequent during pregnancy and postpartum although distributed differently during these epochs.

During the third trimester of pregnancy, there is decreased total sleep time, increased insomnia, and nocturnal awakenings as well as increased daytime sleepiness. Many women report more difficulty falling asleep and maintaining sleep. Sleep is commonly disrupted by general physical discomfort, frequent urination, back and neck pain, vivid dreams, nasal congestion, leg cramps, fetal movements, and uterine contractions. Women with severely disrupted sleep (Wake After Sleep Onset (WASO) score of 15% or more) may have longer labors and are 5.2 times more likely to have C-sections (33).

Snoring increases during pregnancy (54). As many as 14% of pregnant women snore, compared to 4% of non-pregnant women, and 7% report witnessed apneic spells. Predictably, snoring is more common in obese pregnant women than in nonobese pregnant women (79); for obvious anatomical reasons, symptoms of sleep apnea increase significantly from the first trimester to the month of delivery. In the few studies conducted, predictors of sleep apnea were high Body Mass Index (BMI) and change in neck circumference. In a survey of over 500 pregnant women, snoring was reported every day during the last week of pregnancy in 23% of women, as compared to 4% of the same women prior to pregnancy (30). Snorers were more likely to develop hypertension and preeclampsia during pregnancy, as well as growth retardation of the fetus. Comorbid insomnia/habitual snoring were associated with adverse outcomes even after accounting for confounders in a study of pregnant women who reported disturbed sleep (71).

Pregnancy may be associated with sleep apnea. During the third trimester of pregnancy, reduced functional respiratory residual capacity due to weight gain and changes in the shape of the diaphragm and thorax increase the incidence and severity of sleep apnea. Up to 10% of pregnant women are at risk for development of sleep apnea (79), and overweight women and women with a metabolic syndrome are at particular high risk. In a study, 17 women with gestational hypertension were compared to 33 women without hypertension; overnight polysomnography was performed to evaluate for the presence of sleep apnea (17). Those with gestational hypertension were more likely to have sleep apnea (adjusted odds ratio 7.5). A 2011 study of Taiwanese women compared 791 women who had polysomnographically diagnosed sleep apnea to a larger group of women without sleep apnea (19). Pregnant women with sleep apnea showed an increased risk of having preterm and low birth weight infants, with a higher rate of preeclampsia and cesarean sections. Edema in preeclampsia may contribute to development of sleep apnea by causing upper airway obstruction (12).

An emergent body of literature has reported a distinct association between sleep apnea and preeclampsia (21). Preeclamptic toxemia is characterized by hypertension, proteinuria, and edema. Preeclampsia may affect 7% to 10% of all pregnancies in the United States (35) and constitutes a major cause of fetal and maternal morbidity and mortality. Sleep apnea in pregnancy may cause placental hypoxia. It has been hypothesized that placental ischemia is the triggering event in preeclampsia (102). Placental ischemia precipitates a cascade of active factors from the placenta that generate profound effects on the maternal cardiovascular system, causing hypertension and endothelial dysfunction. At the very least, sleep apnea is a significant contributing factor for the development of preeclampsia, in particular in pregnant women who are at high risk.

A study carried out in Buenos Aires, Argentina, investigated with a questionnaire the relationship between snoring, witnessed sleep apneas, and pregnancy-induced hypertension in 456 women (77). The authors found that 156 (35%) of 447 women with singleton pregnancies snored at some point during pregnancy. Snoring was related to pregnancy-induced hypertension and preeclampsia combined, with an adjusted odds ratio of 1.82 (95% CI: 1.16-2.84; p < 0.01). The results were independent of BMI before pregnancy, weight gain during pregnancy, neck circumference, smoking, alcohol use, and age. The authors also found that daytime sleepiness was more prevalent in snoring women and concluded that snoring and witnessed sleep apneas were independently related to pregnancy-induced hypertension.

In a study of 17 women with preeclamptic toxemia and 25 matched women with uncomplicated pregnancy, subjects underwent a nocturnal ambulatory sleep study (using Watch_PAT100) and noninvasive evaluation of endothelial function utilizing the reactive hyperemia test (using Endo_PAT 2000) (102). The authors found that endothelial dysfunction and sleep apnea coexisted in women with preeclamptic toxemia compared with controls and suggested that endothelial dysfunction and sleep-disordered breathing were associated with each other without proving causality.

Although the ultimate study has not been done in pregnant women, it stands to reason that the clinical protocols used to treat sleep apnea in adult nonpregnant women should also be considered in pregnant women. Guilleminault and colleagues conducted a study based on the premise that a significant overlap exists between risk factors for preeclampsia and sleep-disordered breathing (37). The work was a prospective, longitudinal investigation designed to characterize sleep-related breathing patterns in pregnant women with risk factors of preeclampsia and to describe the effects of early nasal CPAP therapy in these patients. Twelve pregnant women with risk factors of preeclampsia underwent polysomnography to identify sleep-related breathing abnormalities and measure baseline blood pressure. Patients with sleep apnea underwent nasal CPAP titration and were treated with optimal pressures. In addition, they received periodic assessments of CPAP compliance and tolerance, sleep quality, and blood pressure control until delivery or onset of preeclampsia. Additional CPAP retitration was performed between weeks 20 and 22 of pregnancy. Based on the study results, the authors concluded that early application of nasal CPAP in pregnant women alleviated sleep-related breathing disturbances but was insufficient to prevent negative pregnancy outcomes. Obesity and prior preeclampsia were associated with the worst complications. In their view, nasal CPAP applications could be beneficial to decrease the severity of outcomes, particularly if individualized to risk factors, like hypertension at the onset of pregnancy.

In a parallel study conducted in Sao Paulo, Brazil, Poyares and colleagues evaluated the possible benefit of CPAP applications in pregnant women with chronic snoring and hypertension early in pregnancy (81). Subjects were randomized to receive either CPAP with standard prenatal care (treatment group) or standard prenatal care alone (control group) with routine obstetric follow-up. In the treatment group (n=7), blood pressure was noted to decrease significantly as compared to the control group, with associated decreases in doses of antihypertensive medications at six months of gestation. All treated patients experienced uncomplicated pregnancies and delivered infants with higher APGAR scores compared to those of controls. The authors concluded that in pregnant women with hypertension and chronic snoring, nasal CPAP applications during the first eight weeks of pregnancy combined with standard prenatal care are associated with better blood pressure control and improved pregnancy outcomes.

In a multicenter open-label, randomized controlled trial, a comparison was made of CPAP treatment versus usual antenatal care (89). Participants included singleton pregnant women older than 18 years of age with any high-risk condition and obstructive sleep apnea. One hundred fifty three and 157 participants were included in the CPAP and usual-care groups. CPAP adherence rate was low: 32.7% with average use of 2.5 h/night. CPAP treatment significantly lowered diastolic blood pressure by -2.2 mmHg. The preeclampsia rate was 13.1% in the CPAP and 22.3% in the usual-care group. The authors concluded that CPAP treatment in women with even mild-to-moderate obstructive sleep apnea and high-risk pregnancy shows reductions in both diastolic blood pressure and the incidence of preeclampsia.

Offspring of mothers with sleep-disordered breathing may have a smaller mean head circumference at birth (-0.95 ± 0.70 vs. -0.30 ± 0.71, P = 0.004) and a distinctive pattern of catchup growth by the end of the first year of life (14). Offspring may also exhibit increased mean adiposity at birth and a distinctive pattern of increased triceps thickness at three years of age. The findings suggest that isolated maternal sleep-disordered breathing during pregnancy may affect longitudinal head circumference growth and adiposity acquisition in the fetus, including the first 3 years of life.

In one study of 686 Asian pregnant women, 43.1% had poor sleep quality, and 11.2% were diagnosed as short sleepers; 19.1% were diagnosed with gestational diabetes mellitus (15). Poor sleep quality and short nocturnal sleep duration were independently associated with increased risk of gestational diabetes mellitus (poor sleep, adjusted OR = 1.75, 95% confidence interval [CI] 1.11 to 2.76; short sleep, adjusted OR = 1.96, 95% CI 1.05 to 3.66). The authors concluded that Asian women with poor sleep quality or short nocturnal sleep duration during pregnancy exhibited a higher prevalence of abnormal glucose regulation.

In a study of 192 pregnant women with a median BMI of 35.14 kg/m² using home sleep testing at 11.14 and 15.35 gestational weeks, respectively, sleep-disordered breathing and insulin resistance were associated in early pregnancy (83). There was a dose-response association between respiratory event index severity and insulin resistance.

Twenty percent to 25% of women experience restless legs syndrome during pregnancy, generally in the second half (88). Symptoms stop soon after delivery, but the occurrence of restless legs syndrome may herald a recurrence later in life. In a Brazilian study, the prevalence of restless legs syndrome during pregnancy was 13.5%, and 90% of the cases started with symptoms during pregnancy. It occurred especially during the third trimester (03). In another study, women who presented with restless legs in a previous pregnancy had a significant 4-fold increased risk of developing chronic restless legs syndrome (16).

In a study of possible risk factors for developing restless legs syndrome in pregnant women, the authors found significantly lower hemoglobin levels with signs of hypochromic anemia typical of iron deficiency in restless legs syndrome-positive respondents to a questionnaire, although oral iron supplementation was significantly higher in this group (63). The overall severity of symptoms correlated inversely with hemoglobin level. They concluded that serum iron level disturbances may play an important role in the pathophysiology of secondary restless legs syndrome in pregnant women.

A systematic review of the prevalence of restless legs syndrome in the third trimester of pregnancy was conducted up to 2019 by Darvishi and colleagues (23). Ten articles capturing 2431 subjects aged 25 to 39 years revealed a prevalence of restless legs syndrome in the third trimester of pregnancy of 22.9% (95% CI:14.7%-33.8%). The prevalence increased as the age of the subjects advanced (P < 0.05).

Opiates are the safest pharmacologic choice for treating restless legs syndrome during pregnancy.

Medications to treat insomnia are generally unsafe during pregnancy. In the classification developed by the United States Food and Drug Administration, drugs are classified according to their known adverse effect on the fetus, both in animals and humans (62). Common hypnotics such as eszopiclone, zaleplon, and zolpidem are categorized as class C drugs; benzodiazepines are categorized as class D; and diphenhydramine, occasionally used to induce sleep, is categorized as class B. Pregnant women who develop severe insomnia should resort to nonpharmacologic measures, such as improving sleep hygiene, exercising as recommended by the obstetrician, and avoiding the supine position in sleep. The snore shirt may be of help. It consists of a T-shirt with three soft cylinders or tennis balls sewed to the back. The discomfort produced when turning on the back forces the individual to sleep on her side. Naps during the day are acceptable if they are short and not too close to bedtime.

In a study, acupuncture significantly improved the sleep quality in pregnant women, possibly through increasing melatonin secretion (29). Acupuncture may be recommended as a low-cost, low-risk treatment alternative.

Much of the concern about using melatonin during pregnancy and breastfeeding stems from animal research. In a meta-analysis, 15 studies on melatonin use in pregnancy and during breastfeeding were reviewed (96). Contrary to what animal studies have suggested, clinical trials that used exogenous melatonin during pregnancy and breastfeeding have not suggested major safety concerns or adverse events. The review emphasizes the need for clinical studies on sleep disorders, including exogenous melatonin, during pregnancy and lactation.

Anesthesia

Obese parturients are prone to anesthetic complications such as aspiration of gastric contents, difficult monitoring, positioning, airway management, and challenging neuraxial techniques. A thorough pre-cesarean delivery preparation should include an evaluation by an anesthesiologist for women with a body mass index over 40 kg/m². Regional anesthesia should ideally be used in all obese parturients unless contraindicated (55).

Acknowledgment

The information in this article has been adapted from articles that originally appeared in Practical Neurology (2009; vol. 8, numbers 5 and 9).

References

01: Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92. PMID 15956009
02: Alonso-Fernandez A, Cerdá Moncadas M, Álvarez Ruiz De Larrinaga A, et al. Impact of obstructive sleep apnea on gestational diabetes mellitus. Arch Bronconeumol 2021:S0300-2896(21)00160-5. PMID 34130878
03: Alves DA, Carvalho LB, Morais JF, Prado GF. Restless legs syndrome during pregnancy in Brazilian women. Sleep Med 2010;11(10):1049-54. PMID 20947424
04: American Academy of Sleep Medicine. International Classification of Sleep Disorders, ICSD-3. 3rd ed. Diagnostic and coding manual. Westchester, Illinois: American Academy of Sleep Medicine, 2014.
05: Arnedt JT, Cuddihy L, Swanson LM, Pickett S, Aikens J, Chervin RD. Randomized controlled trial of telephone-delivered cognitive behavioral therapy for chronic insomnia. Sleep 2013;36(3):353-62. PMID 23450712
06: BaHammam AS, Pandi-Perumal SR, Piper A, et al. Gender differences in patients with obesity hypoventilation syndrome. J Sleep Res 2016;25(4):445-53. PMID 26990045
07: Baker FC, Lee KA. Menstrual cycle effects on sleep. Sleep Med Clin 2018;13(3):283-94. PMID 30098748
08: Baker FC, Lee KA. Menstrual cycle effects on sleep. Sleep Med Clin 2022;17(2):283-94. PMID 35659080
09: Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164(2):196-202. PMID 14744844
10: Bixler EO, Papaliaga MN, Vgontzas AN, et al. Women sleep objectively better than men and the sleep of young women is more resilient to external stressors: effects of age and menopause. J Sleep Res 2009;18(2):221-8. PMID 19302341
11: Bixler EO, Vgontzas AN, Lin HM, et al. Prevalence of sleep-disordered breathing in women: effects of gender. Am J Respir Crit Care Med 2001;163(3 Pt 1):608-13. PMID 11254512
12: Bourjeily G, Ankner G, Mohsenin V. Sleep-disordered breathing in pregnancy. Clin Chest Med 2011;32(1):175-89. PMID 21277458
13: Bourjeily G, El Sabbagh R, Sawan P, et al. Epworth sleepiness scale scores and adverse pregnancy outcomes. Sleep Breath 2013;17(4):1179-86. PMID 23420179
14: Brener A, Lebenthal Y, Levy S, Dunietz GL, Sever O, Tauman R. OR10-01 mild maternal sleep disordered breathing in pregnant women affects growth patterns of head circumference and adiposity during the first three years of life. J Endocr Soc 2020;4(Suppl 1):OR10-01.
15: Cai S, Tan S, Gluckman PD, et al. Sleep quality and nocturnal sleep duration in pregnancy and risk of gestational diabetes mellitus. Sleep 2017;40(2). PMID 28364489
16: Cesnik E, Casetta I, Turri M, et al. Transient RLS during pregnancy is a risk factor for the chronic idiopathic form. Neurology 2010;7;75:2117-20. PMID 21135386
17: Champagne K, Schwartzman K, Opatrny L, et al. Obstructive sleep apnoea and its association with gestational hypertension. Eur Respir J 2009;33(3):559-65. PMID 19213789
18: Chang CC, Chuang HC, Lin CL, et al. High incidence of stroke in young women with sleep apnea syndrome. Sleep Med 2014;15(4):410-4. PMID 24684976
19: Chen YH, Kang JH, Lin CC, Wang IT, Keller JJ, Lin HC. Obstructive sleep apnea and the risk of adverse pregnancy outcomes. Am J Obstet Gynecol 2012;206(2):136.e1-5. PMID 22000892
20: Cohen JM, Jackson CL, Li TY, Wu S, Qureshi AA. Sleep disordered breathing and the risk of psoriasis among US women. Arch Dermatol Res 2015;307(5):433-8. PMID 25676527
21: Culebras A. Sleep disorders: is sleep apnea a risk factor for development of preeclampsia.? Rev Neurol Dis 2008;5(1):32-4. PMID 18418322
22: Culebras A. Sleep apnea and stroke in young women: the many faces of the disorder. Sleep Med 2014;15(4):377-8. PMID 24656910
23: Darvishi N, Daneshkhah A, Khaledi-Paveh B, et al. The prevalence of Restless Legs Syndrome/Willis-ekbom disease (RLS/WED) in the third trimester of pregnancy: a systematic review. BMC Neurol 2020;20(1):132.
24: Davari-Tanha F, Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H. Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. Arch Gynecol Obstet 2016;293(5):1007-13. PMID 26437957
25: Didato G, Giacomo RD, Rosa GJ, Dominese A, de Curtis M, Lanteri P. Restless legs syndrome across the lifespan: symptoms, pathophysiology, management and daily life impact of the different patterns of disease presentation. Int J Environ Res Public Health 2020;17(10):3658. PMID 32456058
26: Driver HS, McLean H, Kumar DV, Farr N, Day AG, Fitzpatrick MF. The influence of the menstrual cycle on upper airway resistance and breathing during sleep. Sleep 2005;28:449-56. PMID 16171289
27: Edwards N, Blyton DM, Hennessy A, Sullivan CE. Severity of sleep-disordered breathing improves following parturition. Sleep 2005;28(6):737-41. PMID 16477961
28: Ehlers CL, Kupfer DJ. Slow-wave sleep: do young adult men and women age differently. J Sleep Res 1997;6(3):211-5. PMID 9358400
29: Foroughinia S, Hessami K, Asadi N, et al. Effect of acupuncture on pregnancy-related insomnia and melatonin: a single-blinded, randomized, placebo-controlled trial. Nat Sci Sleep 2020;12:271-8. PMID 32494210
30: Franklin KA, Holmgren PA, Jönsson F, Poromaa N, Stenlund H, Svanborg E. Snoring, pregnancy-induced hypertension, and growth retardation of the fetus. Chest 2000;117(1):137-41. PMID 10631211
31: Gaillard JM, Blois R. Spindle density in sleep of normal subjects. Sleep 1981;4(4):385-91. PMID 7313391
32: Gao X, Lyall K, Palacios N, Walters AS, Ascherio A. RLS in middle aged women and attention deficit/hyperactivity disorder in their offspring. Sleep Med 2011;12:89-91. PMID 20810309
33: Gay CL, Lee KA, Lee SY. Sleep patterns and fatigue in new mothers and fathers. Biol Res Nurs 2004;5(4):311-8. PMID 15068660
34: Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152(5):463-73. PMID 10981461
35: Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of pre-eclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 2002;9:147-60. PMID 12080413
36: Green SM, Donegan E, Frey BN, et al. Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial. Menopause 2019;26(9):972-80. PMID 31145203
37: Guilleminault C, Palombini L, Poyares D, Takaoka S, Huynh NT, El-Sayed Y. Pre-eclampsia and nasal CPAP: part 1. Early intervention with nasal CPAP in pregnant women with risk-factors for pre-eclampsia: preliminary findings. Sleep Med 2007;9:9-14. PMID 17644420
38: Guthrie KA, Larson JC, Ensrud KE, et al. Effects of pharmacologic and nonpharmacologic interventions on insomnia symptoms and self-reported sleep quality in women with hot flashes: a pooled analysis of individual participant data from four MsFLASH trials. Sleep 2018;41(1). PMID 29165623
39: Hachul H, Brandão Lde C, Bittencourt LR, et al. Clinical profile of menopausal insomniac women referred to sleep laboratory. Acta Obstet Gynecol Scand 2009;88(4):422-7. PMID 19235560
40: Hachul H, Castro LS, Bezerra AG, et al. Hot flashes, insomnia, and the reproductive stages: a cross-sectional observation of women from the EPISONO study. J Clin Sleep Med 2021;17(11):2257-67. PMID 34170233
41: Hu FB, Willett WC, Manson JE, et al. Snoring and risk of cardiovascular disease in women. J Am Coll Cardiol 2000;35(2):308-13. PMID 10676674
42: Hurley S, Goldberg D, Bernstein L, Reynolds P. Sleep duration and cancer risk in women. Cancer Causes Control 2015;26(7):1037-45. PMID 25924583
43: Javaheri S. Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report. Int J Cardiol 2006;106(1):21-8. PMID 25914563
44: Jennum P, Tønnesen P, Ibsen R, Kjellberg J. All-cause mortality from obstructive sleep apnea in male and female patients with and without continuous positive airway pressure treatment: a registry study with 10 years of follow-up. Nat Sci Sleep 2015;7:43-50. PMID 25914563
45: Kalmbach DA, Cheng P, Arnedt JT, et al. Treating insomnia improves depression, maladaptive thinking, and hyperarousal in postmenopausal women: comparing cognitive-behavioral therapy for insomnia (CBTI), sleep restriction therapy, and sleep hygiene education. Sleep Med 2019;55:124-34. PMID 30785053
46: Kapsimalis F, Kryger MH. Gender and obstructive sleep apnea syndrome, part 2: mechanisms. Sleep 2002;25(5):497-504. PMID 12150315
47: Kendle AM, Salemi JL, Jackson CL, Buysse DJ, Louis JM. Insomnia during pregnancy and severe maternal morbidity in the United States: nationally representative data from 2006 to 2017. Sleep 2022;45(10):zsac175. PMID 35901516
48: Kidron D, Bar-Lev Y, Tsarfaty I, Many A, Tauman R. The effect of maternal obstructive sleep apnea on the placenta. Sleep 2019;42(6):pii: zsz072. PMID 30903184
49: Lee KA, Gay CL. Sleep in late pregnancy predicts length of labor and type of delivery. Am J Obstet Gynecol 2004;191(6):2041-6. PMID 15592289
50: Li Y, Li Y, Winkelman JW, et al. Prospective study of restless legs syndrome and total and cardiovascular mortality among women. Neurology 2018;90(2):e135-41. PMID 29247069
51: Liamsombut S, Tantrakul V. Sleep disturbance in pregnancy. Sleep Med Clin 2022;17(1):11-23. PMID 35216757
52: Ljunggren M, Lindberg E, Franklin KA, et al. Obstructive sleep apnea during REM sleep is associated with early signs of atherosclerosis in women. Sleep 2018;14(7). PMID 29762755
53: Lombardi C, Meriggi P, Agostoni P, et al. High-altitude hypoxia and periodic breathing during sleep: gender-related differences. J Sleep Res 2013;22(3):322-30. PMID 23294420
54: Loube DI, Poceta JS, Morales MC, Peacock MD, Mitler MM. Self-reported snoring in pregnancy. Association with fetal outcome. Chest 1996;109(4):885-9. PMID 8635365
55: Loubert C, Fernando R. Cesarean delivery in the obese parturient: anesthetic considerations. Womens Health (Lond Engl) 2011;7:163-79. PMID 21410344
56: Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 2024;391(15):1464. PMID 38912654
57: Manber R, Armitage R. Sex, steroids, and sleep: a review. Sleep 1999;22(5):540-55. PMID 10450590
58: Manber R, Bootzin RR. Sleep and the menstrual cycle. Health Psychol 1997;16:209-14. PMID 9152698
59: Manconi M, van der Gaag LC, Mangili F, et al. Sleep and sleep disorders during pregnancy and postpartum: the Life-ON study. Sleep Med 2024;113:41-8. PMID 37984016
60: Martin JL, Badr MS, Zeineddine S. Sleep disorders in women veterans. Sleep Med Clin 2018;13(3):433-41. PMID 30098757
61: Matthews KA, Lee L, Kravitz HM, et al. Influence of the menopausal transition on polysomnographic sleep characteristics: a longitudinal analysis. Sleep 2021;44(11):zsab139. PMID 34081126
62: Meadows M. Pregnancy and the drug dilemma. FDA Consum 2001;35(3):16-20. PMID 11458544
63: Minar M, Košutzká Z, Habánová H, Rusňák I, Planck K, Valkovič P. Restless legs syndrome in pregnancy is connected with iron deficiency. Sleep Med 2015;16(5):589-92. PMID 25900141
64: Mindell JA, Cook RA, Nikolovski J. Sleep patterns and sleep disturbances across pregnancy. Sleep Med 2015;16(4):483-8. PMID 25666847
65: Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323-7. PMID 14592194
66: National Sleep Foundation. Sleep in America Poll. In: http://www.sleepfoundation.org/article/sleep-america-polls/2010-sleep-and-ethnicity, 2007.
67: Neau JP, Marion P, Mathis S, et al. Restless legs syndrome and pregnancy: follow-up of pregnant women before and after delivery. Eur Neurol 2010;64:361-6. PMID 21088424
68: Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288(7):872-81. PMID 12186605
69: Nowakowski S, Matthews KA, von Känel R, Hall MH, Thurston RC. Sleep characteristics and inflammatory biomarkers among midlife women. Sleep 2018;41(5). PMID 29617910
70: Okun ML, Buysse DJ, Hall MH. Identifying insomnia is early pregnancy: validation of the Insomnia Symptoms Questionnaire (ISQ) in pregnant women. J Clin Sleep Med 2015;11(6):645-54. PMID 25766716
71: Okun ML, O'Brien LM. Concurrent insomnia and habitual snoring are associated with adverse pregnancy outcomes. Sleep Med 2018;46:12-9. PMID 29773206
72: Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006;166:1262-8. PMID 16801508
73: Pan Z, Wen S, Qiao X, Yang M, Shen X, Xu L. Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis. Menopause 2022;29(5):627-35. PMID 35102100
74: Patrick LR. Restless legs syndrome: pathophysiology and the role of iron and folate. Altern Med Rev 2007;12:101-21. PMID 17604457
75: Pennestri MH, Montplaisir J, Colombo R, et al. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology 2007;68:1213-8. PMID 17420405
76: Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013;177(9):1006-14. PMID 23589584
77: Perez-Chada D, Videla AJ, O'Flaherty ME, et al. Snoring, witnessed sleep apnoeas and pregnancy-induced hypertension. Acta Obstet Gynecol Scand 2007;86(7):788-92. PMID 17611822
78: Pichler I, Hicks AA, Pramstaller PP. Restless legs syndrome: an update on genetics and future perspectives. Clin Genet 2008;73:297-305. PMID 18070136
79: Pien GW, Fife D, Pack AI, Nkwuo JE, Schwab RJ. Changes in symptoms of sleep-disordered breathing during pregnancy. Sleep 2005;28(10):1299-305. PMID 16295215
80: Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. J Appl Physiol 1998;84(3):1055-62. PMID 9480969
81: Poyares D, Guilleminault C, Hachul H, et al. Pre-eclampsia and nasal CPAP: part 2. Hypertension during pregnancy, chronic snoring, and early nasal CPAP intervention. Sleep Med 2007;9:15-21. PMID 17644475
82: Salari N, Hasheminezhad R, Hosseinian-Far A, et al. Global prevalence of sleep disorders during menopause: a meta-analysis. Sleep Breath 2023;27(5):1883-97. PMID 36892796
83: Sanapo L, Bublitz MH, Bai A, et al. Association between sleep disordered breathing in early pregnancy and glucose metabolism. Sleep 2022;45(4):zsab281. PMID 35934505
84: Sarti CD, Chiantera A, Graziottin A, et al. Hormone therapy and sleep quality in women around menopause. Menopause 2005;12(5):545-51. PMID 16145308
85: Schenck CH, Hurwitz TD, O'Connor KA, Mahowald MW. Additional categories of sleep-related eating disorders and the current status of treatment. Sleep 1993;16:457-66. PMID 8104356
86: Siguroardottir ES, Gislason T, Benediktsdottir B, et al. Female sex hormones and symptoms of obstructive sleep apnea in European women of a population-based cohort. PLoS One 2022;17(6):e0269569. PMID 35731786
87: Spira AP, Stone KL, Redline S, et al. Actigraphic sleep duration and fragmentation in older women: associations with performance across cognitive domains. Sleep 2017;40(8). PMID 28472447
88: Suzuki K, Ohida T, Sone T, et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003;26:673-7. PMID 14572119
89: Tantrakul V, Ingsathit A, Liamsombut S, et al. Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial. Respir Res 2023;24(1):171. PMID 37370135
90: Terauchi M, Cheng JY, Yardley J, et al. Efficacy and safety of lemborexant in midlife women with insomnia disorder. Menopause 2023;30(8):839-48. PMID 37339396
91: Thurston RC, Chang Y, von Känel R, et al. Sleep characteristics and carotid atherosclerosis among midlife women. Sleep 2017;40(2). PMID 28364498
92: Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68:301-3. PMID 17242339
93: Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302. PMID 18925578
94: Unnarsdóttir AB, Hauksdóttir A, Aspelund T, et al. Sleep disturbances among women in a Subarctic region: a nationwide study. Sleep 2022;45(8):zsac100. PMID 35532192
95: Villar-Martinez MD, Pérez-Lorensu PJ, Moreno-Ajona D, Pueyo-Morlans M, Carrillo-Padilla FJ. Menstruation-related hypersomnia. Electroencephalographic and actigraphic correlation in an underrecognized neuropsychiatric disorder. Sleep Med 2022;91:93-5. PMID 35294863
96: Vine T, Brown GM, Frey BN. Melatonin use during pregnancy and lactation: A scoping review of human studies. Braz J Psychiatry 2022;44(3):342-8. PMID 34730672
97: Wang P, Ren FM, Lin Y, et al. Night-shift work, sleep duration, daytime napping, and breast cancer risk. Sleep Med 2015;16(4):462-8. PMID 25794454
98: Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Restless legs syndrome is associated with long-COVID in women. J Clin Sleep Med 2022;18(5):1413-8. PMID 35484639
99: Winkelman JW. Clinical and polysomnographic features of sleep-related eating disorder. J Clin Psychiatry 1998;59:14-9. PMID 9491060
100: Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-9. PMID 16931507
101: Yan LX, Chen XR, Chen B, et al. Gender-specific association of sleep duration with body mass index, waist circumference, and body fat in chinese adults. Biomed Environ Sci 2017;30(3):157-69. PMID 28427485
102: Yinon D, Lowenstein L, Suraya S, et al. Pre-eclampsia is associated with sleep-disordered breathing and endothelial dysfunction. Eur Respir J 2006;27(2):328-33. PMID 16452588
103: Young WB. Allodynia as a complication of migraine: background and management. Curr Treat Options Neurol 2009;11:3-9. PMID 19094830
104: Zaremba S, Mueller N, Heisig A, et al. Elevated upper body position improves pregnancy related obstructive sleep apnea without impairing sleep quality or sleep architecture early after delivery. Chest 2015;148(4):936-44. PMID 25905714
105: Zhang B, Wing YK. Sex differences in insomnia: a meta-analysis. Sleep 2006;29:85-93. PMID 16453985

ICD & OMIM codes

ICD-10: Obstructive sleep apnea: G47.3

Restless legs syndrome: G25.8

Disorders of initiating and maintaining sleep: G47.0
ICD-11: Obstructive sleep apnoea: 7A41

Restless legs syndrome: 7A80

Insomnia disorders, unspecified: 7A0Z

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Sleep disorders in women

Also Relevant

Insomnia
Periodic limb movements
Pharmacological treatment of insomnia
Restless legs syndrome
Sex hormones and the nervous system
- Sleep disorders
- Sleep-related eating disorder

Clinical Categories

Sleep Disorders

Sleep disorders in women

Sleep disorders in women

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Epochs

Sleep disorders

Prognosis and complications

Biological basis

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Acknowledgment

Media

References

Contributors

Author

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Telehealth and cognitive behavioral therapy for insomnia (CBT-I)

NonREM parasomnias

Neurologic disorders associated with obesity

Hypersomnolence

Sleep, stroke, and vascular dementia

Parasomnia overlap disorder and status dissociatus

Stimulant-dependent sleep disorder

Fatal familial insomnia

Sleep disorders in women

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Epochs

Sleep disorders

Prognosis and complications

Biological basis

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Acknowledgment

Media

References

Contributors

Author

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Telehealth and cognitive behavioral therapy for insomnia (CBT-I)

NonREM parasomnias

Neurologic disorders associated with obesity

Hypersomnolence

Sleep, stroke, and vascular dementia

Parasomnia overlap disorder and status dissociatus

Stimulant-dependent sleep disorder

Fatal familial insomnia

This is an article preview.
Start a Free Account
to access the full version.